Moreover, the 36-month beta value for TBPH is 0.26. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 2 as “sell.”
The public float for TBPH is 45.01M and currently, short sellers hold a 12.38% of that float. On September 02, 2024, TBPH’s average trading volume was 407.91K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TBPH) stock’s latest price update
Theravance Biopharma Inc (NASDAQ: TBPH)’s stock price has gone rise by 0.49 in comparison to its previous close of 8.21, however, the company has experienced a 1.98% increase in its stock price over the last five trading days. prnewswire.com reported 2024-08-27 that DUBLIN, Aug. 27, 2024 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City on Tuesday, September 10 at 10:00 am ET (7:00 am PT/3:00 pm IST) and will be hosting in-person meetings with the investment community at the conference.
TBPH’s Market Performance
Theravance Biopharma Inc (TBPH) has experienced a 1.98% rise in stock performance for the past week, with a -17.75% drop in the past month, and a -4.29% drop in the past quarter. The volatility ratio for the week is 2.93%, and the volatility levels for the past 30 days are at 4.21% for TBPH. The simple moving average for the past 20 days is 0.03% for TBPH’s stock, with a -11.87% simple moving average for the past 200 days.
Analysts’ Opinion of TBPH
Many brokerage firms have already submitted their reports for TBPH stocks, with Leerink Partners repeating the rating for TBPH by listing it as a “Market Perform.” The predicted price for TBPH in the upcoming period, according to Leerink Partners is $10 based on the research report published on August 06, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see TBPH reach a price target of $21. The rating they have provided for TBPH stocks is “Buy” according to the report published on April 12th, 2024.
TBPH Trading at -7.14% from the 50-Day Moving Average
After a stumble in the market that brought TBPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.55% of loss for the given period.
Volatility was left at 4.21%, however, over the last 30 days, the volatility rate increased by 2.93%, as shares sank -14.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.73% lower at present.
During the last 5 trading sessions, TBPH rose by +1.98%, which changed the moving average for the period of 200-days by -19.12% in comparison to the 20-day moving average, which settled at $8.18. In addition, Theravance Biopharma Inc saw -26.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TBPH starting from Samaha Eli, who purchase 999,800 shares at the price of $7.80 back on Aug 07 ’24. After this action, Samaha Eli now owns 9,511,150 shares of Theravance Biopharma Inc, valued at $7,798,440 using the latest closing price.
Farnum Rhonda, the SVP, COMM & MEDICAL AFFAIRS of Theravance Biopharma Inc, sale 4,000 shares at $9.00 during a trade that took place back on Jul 10 ’24, which means that Farnum Rhonda is holding 335,965 shares at $36,000 based on the most recent closing price.
Stock Fundamentals for TBPH
Current profitability levels for the company are sitting at:
- -0.63 for the present operating margin
- 0.86 for the gross margin
The net margin for Theravance Biopharma Inc stands at -0.74. The total capital return value is set at -0.11. Equity return is now at value -19.27, with -11.29 for asset returns.
Based on Theravance Biopharma Inc (TBPH), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -0.19. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -31.24.
Currently, EBITDA for the company is -40.28 million with net debt to EBITDA at -0.01. When we switch over and look at the enterprise to sales, we see a ratio of 6.51. The receivables turnover for the company is 4.34for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.20.
Conclusion
To wrap up, the performance of Theravance Biopharma Inc (TBPH) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
